Abstract
Dyslipoproteinemias play a very prominent role in the pathogenesis of atherosclerosis in postmenopausal women; These lose the cardiovascular protection of estrogens, increasing the risk of developing atherothrombotic vascular disease (CVD). International guidelines do not vary between the management of dyslipidemia between men and women, but these are treated less vigorously and without taking into account the postmenopausal hormonal situation. Its management must be included in the individual risk of each woman, with the new LDL goals and above all take into account Lipoproteins rich in Triglycerides (LPRTG) that are associated with the classic modifiable risk factors, in a non-modifiable biological terrain such as are age and genetic family history; which may be associated with emerging factors such as Lipoprotein “a” (Lp a), hyperhomocysteine, elevated CRP (C-reactive protein), among other factors that are rarely taken into account. Statins demonstrated their effectiveness in reducing LDL and even increasing HDL, reducing cardio and cerebrovascular events, but a good percentage of patients, despite the intensified doses, remain at Residual Lipid Risk, so we must resort to new therapeutic targets. like biological ones.